| 04.28.23 | Lilly launches head-to-head obesity trial against Novo Nordisk; Novartis axes 10% of pipeline, narrows R&D

Click here to subscribe to Fiercebiotech.com

1 year ago

Html
Text

Weekly Digest

Deep learning methods reveal hidden patterns to improve rare disease detection.

Improve patient pattern characterization, classification and augmentation. Download: CONAN - Complementary pattern augmentation for rare disease detection.

This Week

Apr 28, 2023

In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy

Novartis prunes assets, axing 10% of pipeline programs to narrow R&D focus

Johnson & Johnson eyes $40B valuation for consumer health group Kenvue: WSJ

Biogen 'could migrate' from neuroscience to immunology, with $10B 'dry powder'

Bristol Myers' Giovanni Caforio to hand CEO baton to commercial chief Chris Boerner

Novartis pens $425M biobucks deal with German biotech, scooping up more radiopharmaceutical tech

Roche's Genentech opens up the world with new ad for Vabysmo

Know Labs’ noninvasive diabetes sensor tech aces proof-of-concept tests

Amid Pluvicto shortage, FDA quickly clears Novartis manufacturing facility

Glimpse of success? Life Biosciences' gene therapy restores visual function in primates with eye disorder


A message from Digital Pharma East

Featured

In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy

By Angus Liu

Eli Lilly quietly registered a new phase 3b trial pitting its Mounjaro against Novo Nordisk’s weight loss drug Wegovy in overweight or obese patients, teeing up an epic fight in a multibillion-dollar market.

Novartis prunes assets, axing 10% of pipeline programs to narrow R&D focus

By Nick Paul Taylor

Novartis has undertaken an old-fashioned decimation of its pipeline. The Swiss drugmaker has decided to dump or out-license 10% of its R&D projects to narrow its sights on five core therapeutic areas and focus investment on its most promising programs within those spaces.

Johnson & Johnson eyes $40B valuation for consumer health group Kenvue: WSJ

By Kevin Dunleavy

As its Kenvue spinoff nears, J&J is conducting an IPO roadshow this week to drum up interest from investors, sources told The Wall Street Journal. They also said J&J hopes to raise at least $3.5 billion in the offering at a valuation of $40 billion.

Biogen 'could migrate' from neuroscience to immunology, with $10B 'dry powder'

By Annalee Armstrong

Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday.

Webinar: Industry 4.0 and its impact on packaging and traceability

Tuesday, May 2, 2023 | 11am ET / 8am PT

In this webinar, we will discuss how tech-enabled traceability enables digitalization beyond tracking and tracing pharma drugs through the supply chain by leveraging Industry 4.0-equipped operations. Register now.

Bristol Myers' Giovanni Caforio to hand CEO baton to commercial chief Chris Boerner

By Angus Liu

In a surprise announcement Wednesday, Bristol Myers Squibb said CEO Giovanni Caforio will end his eight-year tenure and hand the baton to chief commercialization officer Chris Boerner.

Novartis pens $425M biobucks deal with German biotech, scooping up more radiopharmaceutical tech

By Gabrielle Masson

Novartis is doling out $40 million cash for exclusive licensing rights to 3B Pharmaceuticals’ cancer-targeting tech, wrapping up some loose ends for a radiotherapy picked up from Clovis Oncology at the end of last year.

Roche's Genentech opens up the world with new ad for Vabysmo

By Sharon Klahr Coey

Adults facing wet age-related macular degeneration and diabetic macular edema fear their world getting smaller, due to loss of eyesight. Roche’s Genentech addresses that issue head-on in its first DTC ad for Vabysmo.

Know Labs’ noninvasive diabetes sensor tech aces proof-of-concept tests

By Andrea Park

Know Labs is one step closer to bringing its noninvasive glucose monitoring technology to the masses.

Amid Pluvicto shortage, FDA quickly clears Novartis manufacturing facility

By Angus Liu

After a shortage prevented prostate cancer patients from getting Novartis’ Pluvicto, the FDA has quickly approved a radiotherapy manufacturing facility to help the company ramp up commercial supply.

Glimpse of success? Life Biosciences' gene therapy restores visual function in primates with eye disorder

By Helen Floersh

Preclinical success in primates could put a new gene therapy on the path to becoming the first-ever treatment for non-arteritic anterior ischemic optic neuropathy, along with many other aging diseases of the eye.

Fierce podcasts

Don't miss an episode

'The Top Line': A special series on Narcan, the life-saving nasal spray

This week on "The Top Line," we're launching a mini-series on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription.

'Podnosis': Progress for the opioid crisis, and why we need antimicrobial stewardship programs

'The Top Line': How Pfizer became the first in Big Pharma history to break $100B in sales, plus this week's headlines

Webinar: Bringing it home: Accelerating and transforming the paradigm of clinical research

Tuesday, May 9, 2023 | 1pm ET / 10am PT

Learn how a leading precision diagnostic testing company is partnering with an in-home care provider to accelerate and reduce the cost of clinical research. Hear about unique approaches in moving complex clinical trials and treatment into the home to create efficiencies and scale in patient recruitment, engagement, outcomes, and satisfaction. Register now.

Resources

Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?

Accelerated Approval Pathways Pose Commercialization Risk

Accelerated approval pathways create an additional layer of complexity in the chaotic oncology marketplace, leaving manufacturers of all sizes seeking a new commercialization model for launch success.

The Hematopoietic Colony Forming Cell (CFC) Assay for Drug Safety and Toxicity

The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process

Sponsored by: ReachBio | The Cell Biology Experts™

Whitepaper

Accessing and Analyzing Relevant Content in Today’s Information Chaos – R&D Challenges and Opportunities

We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing?

Blueprint for Commercializing Cell and Gene Therapies

How advanced medicines commercial readiness differs and the resources needed to maximize potential.

Coming to America: Keys to Success for ex-US Digital Health Companies Entering the US Market

This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.